Patiromer
end-stage kidney disease, hyperkalemia
END-STAGE KIDNEY DISEASE
Patiromer was FDA-approved in 2015 and has been tested extensively in the management of chronic hyperkalemia [The OPAL-HK [To date, only one randomized controlled trial has investigated patiromer in the setting of acute hyperkalemia, in end-stage kidney disease patients. Rafique et al. reported significant decrease in serum K